Phase Ii Trial Of Bevacizumab In Patients With Surgery And Radiation Refractory Progressive Meningioma.

2055 Background: Systemic treatment options are limited for meningiomas that progress following surgery and radiotherapy. VEGF is associated with neovascularization, tumor growth, and edema in meningioma. This prospective phase II study was undertaken to determine the efficacy of bevacizumab (BEV), a VEGF ligand binding monoclonal antibody, in patients with progressive benign (BM), atypical (AM), and malignant meningioma (MM) as measured by median 6-month progression free survival (PFS-6). Secondary endpoints included median progression free survival (mPFS), median overall survival (mOS), and radiographic response rate. Methods: Patients with histologically confirmed BM, AM, or MM with radiographic progression were eligible. There was no limit on prior therapies. BEV was administered 10 mg/kg intravenously every two weeks. After 6 months of therapy, stable patients were eligible to switch to an every 3-week schedule of BEV (15 mg/kg). Clinical examination and imaging were performed every 4 and 8 weeks res...